Benralizumab and Omalizumab: Dual Biologic Therapy in ABPA and Urticaria

CSU and ABPA seem to have different Type 2 pathogeneses but they can be present at the same time. Here we report a clinical case of a 60-year-old woman affected by ABPA and CSU not controlled by either omalizumab or benralizumab alone. After a 18-month follow-up period of omalizumab and benralizumab combined therapy, both diseases were satisfyingly controlled. The dual biological therapy may be feasible and safe in patients suffering from different diseases contemporarily and uncontrolled by a single therapy. Targeting two different aspects of Type 2 pathogenesis, IgE and IL-5r, provided beneficial control of both diseases with no adverse effects.